What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Yu Shyr mainly focuses on Internal medicine, Cancer research, Surgery, Gastroenterology and Endocrinology.
His Internal medicine research includes elements of Oncology and Cardiology.
His Cancer research study combines topics in areas such as Endothelial stem cell, Transforming growth factor, Transforming growth factor beta and CD8.
His Surgery study integrates concerns from other disciplines, such as Incidence and Confidence interval.
His research investigates the link between Gastroenterology and topics such as Colorectal cancer that cross with problems in Adenoma and Odds ratio.
His Endocrinology research is multidisciplinary, relying on both Immune system and C-reactive protein.
His most cited work include:
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies (2858 citations)
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib (1661 citations)
- Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. (1219 citations)
What are the main themes of his work throughout his whole career to date?
Yu Shyr mainly investigates Internal medicine, Cancer research, Cancer, Oncology and Pathology.
The various areas that he examines in his Internal medicine study include Gastroenterology, Endocrinology and Surgery.
His work on Cancer research is being expanded to include thematically relevant topics such as Carcinogenesis.
His work carried out in the field of Oncology brings together such families of science as Carboplatin, Regimen, Paclitaxel, Breast cancer and Adenocarcinoma.
His Pathology study frequently draws connections between related disciplines such as Metastasis.
His Hemodialysis research incorporates elements of Prospective cohort study and Kidney disease.
He most often published in these fields:
- Internal medicine (34.25%)
- Cancer research (17.21%)
- Cancer (16.88%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (34.25%)
- Cancer research (17.21%)
- Cancer (16.88%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Cancer research, Cancer, Oncology and Computational biology are his primary areas of study.
Many of his studies on Internal medicine apply to Endocrinology as well.
His work in Cancer research covers topics such as Phases of clinical research which are related to areas like Cediranib.
His work in the fields of Cancer, such as Breast cancer, overlaps with other areas such as Severe acute respiratory syndrome coronavirus 2 and 2019-20 coronavirus outbreak.
The Oncology study combines topics in areas such as Adverse effect, Clinical endpoint, Proportional hazards model, Triple-negative breast cancer and Adenocarcinoma.
The concepts of his Computational biology study are interwoven with issues in Bioinformatics, RNA, Genotyping, Single-nucleotide polymorphism and DNA sequencing.
Between 2015 and 2021, his most popular works were:
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection (441 citations)
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade (257 citations)
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy (215 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Internal medicine, Computational biology, Cancer research, Gene and Cancer.
His Internal medicine research integrates issues from Endocrinology, Oncology and Cardiology.
The study incorporates disciplines such as Breast cancer, Triple-negative breast cancer, Metastasis and Gene expression profiling in addition to Oncology.
He studies Cancer research, focusing on Melanoma in particular.
Yu Shyr focuses mostly in the field of Gene, narrowing it down to matters related to Pathology and, in some cases, Retinoblastoma, PTEN and Mutation.
His Cancer research is multidisciplinary, incorporating perspectives in Lung cancer, Cisplatin and Statistical significance.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
